Generating RWE for Better Healthcare Decisions: OXON at ISPOR Europe 2026

8–11 November 2026 | Austria Center Vienna, Austria | Booth #831

How can real-world data provide the evidence needed to assess the value, effectiveness and safety of healthcare interventions?

This question is central to the work of OXON Epidemiology, which will be exhibiting at ISPOR Europe 2026, taking place in Vienna from 8 to 11 November.

Under the theme Shaping the Future of Access Through Science and Policy, this year’s congress brings together professionals in Health Economics and Outcomes Research (HEOR) to explore how robust scientific evidence can inform healthcare decisions and improve patient access to effective treatments.

Bridging Real-World Data and Decision-Relevant Evidence

As healthcare systems face growing demands for robust, decision-relevant evidence, Real-World Evidence (RWE) plays an increasingly important role in clinical, regulatory, Health Technology Assessment (HTA) and market access strategies.

At OXON, we support pharmaceutical and biotechnology companies in developing evidence generation programmes that address questions extending beyond traditional clinical trials.

Our expertise spans epidemiology, real-world evidence (RWE), biostatistics and evidence synthesis, helping clients investigate treatment effectiveness, comparative effectiveness, safety, healthcare resource utilisation and patient outcomes in real-world settings. Through rigorous methodologies and integrated scientific and operational capabilities, we help transform complex real-world data into reliable evidence that supports informed healthcare decision-making.

Key Focus Areas at ISPOR Europe 2026

At this year’s congress, we look forward to discussing some of the key challenges in generating evidence to support healthcare decision-making:

• Real-World Evidence and Observational Research: Generating robust evidence on treatment effectiveness, safety, disease burden and patient outcomes in routine clinical practice.
• Comparative Effectiveness and External Comparators: Applying rigorous methodologies to assess treatment effects, particularly when randomised comparative evidence is limited.
• HTA and Market Access Evidence: Addressing evidence gaps and supporting evidence generation strategies aligned with the needs of HTA bodies and healthcare decision-makers.
• Evidence Synthesis and Biostatistics: Combining evidence from multiple sources and applying robust statistical methods to support reliable interpretation and decision-making.

Connect with OXON at ISPOR Europe 2026

Our team will be available at Booth #831 to discuss your RWE research needs, from evidence strategy and study design through to analysis and reporting.

Whether you are addressing evidence gaps, planning an international observational study or developing evidence to support HTA and market access decisions, we would welcome the opportunity to explore how OXON can support your objectives.

We look forward to meeting you in Vienna!